Brief: Milestone Pharmaceuticals Submits Response To The FDA’s CRL For CARDAMYST (Etripamil) Nasal Spray For PSVT Following Type A Meeting
16/06/2025 13:05
June 16 (Reuters) - Milestone Pharmaceuticals Inc MIST.O: MILESTONE PHARMACEUTICALS SUBMITS RESPONSE TO THE FDA’S CRL FOR CARDAMYST (ETRIPAMIL) NASAL SPRAY FOR PSVT FOLLOWING TYPE A MEETING MILESTONE PHARMACEUTICALS INC - FDA TO DETERMINE ACCEPTANCE OF RESPONSE AND PDUFA DATE WITHIN 30 DAYS MILESTONE PHARMACEUTICALS INC - REVIEW TIME EXPECTED TO BE WITHIN 2 OR 6 MONTHS FROM RESUBMISSION MILESTONE PHARMACEUTICALS INC: BELIEVE TYPE A MEETING WITH FDA PROVIDED GUIDANCE TO SUBMIT RESPONSE TO CRL DIRECTLY AFTER MEETING Source text: ID:nGNX3T4VhX Further company coverage: MIST.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Milestone Pharmaceuticals
See all newsBrief: Milestone Pharmaceuticals Announces First European Study Participant Enrolled In Revera-301 Phase 3 Clinical Trial
Brief: Milestone Pharmaceuticals Says NMPA Approval Triggers $2 Mln Milestone Payment To The Co
Milestone Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Canada's Milestone Pharma misses Q2 product revenue expectations
Milestone Pharmaceuticals Inc expected to post a loss of 19 cents a share - Earnings Preview